Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1714

1.

National Data on Social Risk Screening Underscore the Need for Implementation Research.

Gold R, Gottlieb L.

JAMA Netw Open. 2019 Sep 4;2(9):e1911513. doi: 10.1001/jamanetworkopen.2019.11513. No abstract available.

PMID:
31532510
2.

Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases.

Motte J, Kneiphof J, Straßburger-Krogias K, Pitarokoili K, Fisse AL, Kappos L, Gold R.

Ther Adv Neurol Disord. 2019 Aug 24;12:1756286419872115. doi: 10.1177/1756286419872115. eCollection 2019.

3.

Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis.

Ayzenberg I, Ellrichmann G, Schroeder C, Tönges L, Klasing A, Pappa V, Brück W, Gold R.

Front Neurol. 2019 Aug 2;10:829. doi: 10.3389/fneur.2019.00829. eCollection 2019.

4.

Dermoscopy of primary cutaneous intravascular large B-cell lymphoma.

Llamas-Velasco M, Held L, Gold R, Paredes B.

Clin Exp Dermatol. 2019 Aug 16. doi: 10.1111/ced.14073. [Epub ahead of print]

PMID:
31419326
5.

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.

Faissner S, Plemel JR, Gold R, Yong VW.

Nat Rev Drug Discov. 2019 Aug 9. doi: 10.1038/s41573-019-0035-2. [Epub ahead of print] Review.

PMID:
31399729
6.

Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.

Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M.

BMC Neurol. 2019 Aug 9;19(1):190. doi: 10.1186/s12883-019-1407-2.

7.

Utilizing Student Health and Academic Data: A County-Level Demonstration Project.

Carter-Pokras OD, Bugbee BA, Gold RS, Lauver PE, Aiken R, Arria AM.

Health Promot Pract. 2019 Aug 9:1524839919862796. doi: 10.1177/1524839919862796. [Epub ahead of print]

PMID:
31394957
8.

Heterogeneous GBS course requires standardized guidelines.

Pitarokoili K, Gold R.

Nat Rev Neurol. 2019 Jul 29. doi: 10.1038/s41582-019-0245-6. [Epub ahead of print] No abstract available.

PMID:
31358946
9.

Fingolimod for Irradiation-Induced Neurodegeneration.

Metzdorf J, Hobloss Z, Schlevogt S, Ayzenberg I, Stahlke S, Pedreiturria X, Haupeltshofer S, Gold R, Tönges L, Kleiter I.

Front Neurosci. 2019 Jul 9;13:699. doi: 10.3389/fnins.2019.00699. eCollection 2019.

10.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
11.

Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy.

Pitarokoili K, Sturm D, Labedi A, Greiner T, Eitner L, Kumowski N, Enax-Krumova EK, Fisse AL, Maier C, Gold R, Tegenthoff M, Schmidt-Wilcke T, Yoon MS.

Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419855485. doi: 10.1177/1756286419855485. eCollection 2019.

12.

Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.

Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L.

J Neural Transm (Vienna). 2019 Jul;126(7):879-888. doi: 10.1007/s00702-019-02034-8. Epub 2019 Jun 20.

PMID:
31222604
13.

Cell sorting actuated by a microfluidic inertial vortex.

Pritchard RH, Zhukov AA, Fullerton JN, Want AJ, Hussain F, la Cour MF, Bashtanov ME, Gold RD, Hailes A, Banham-Hall E, Rogers SS.

Lab Chip. 2019 Jul 9;19(14):2456-2465. doi: 10.1039/c9lc00120d.

PMID:
31210196
14.

Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy.

Ambrosius B, Gold R, Chan A, Faissner S.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 4;6(3):e551. doi: 10.1212/NXI.0000000000000551. eCollection 2019 May.

15.

Role of Health Information Technology in Addressing Health Disparities: Patient, Clinician, and System Perspectives.

Zhang X, Hailu B, Tabor DC, Gold R, Sayre MH, Sim I, Jean-Francois B, Casnoff CA, Cullen T, Thomas VA Jr, Artiles L, Williams K, Le PT, Aklin CF, James R.

Med Care. 2019 Jun;57 Suppl 6 Suppl 2:S115-S120. doi: 10.1097/MLR.0000000000001092.

PMID:
31095049
16.

Social Relationships and Functional Impairment in Aging Cancer Survivors: A Longitudinal Social Network Study.

Guida JL, Holt CL, Dallal CM, He X, Gold R, Liu H.

Gerontologist. 2019 May 3. pii: gnz051. doi: 10.1093/geront/gnz051. [Epub ahead of print]

PMID:
31050729
17.

Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?

Nakahara J, Tomaske L, Kume K, Takata T, Kamada M, Deguchi K, Kufukihara K, Schneider R, Gold R, Ayzenberg I.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e559. doi: 10.1212/NXI.0000000000000559. eCollection 2019 May.

18.

Bringing Social Context into Diabetes Care: Intervening on Social Risks versus Providing Contextualized Care.

Hessler D, Bowyer V, Gold R, Shields-Zeeman L, Cottrell E, Gottlieb LM.

Curr Diab Rep. 2019 Apr 29;19(6):30. doi: 10.1007/s11892-019-1149-y. Review.

PMID:
31037356
19.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
20.

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis.

Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, Schrewe L, Guse K, Ahmadi F, Demir S, Laverick L, Gresle M, Worley P, Reichardt HM, Butzkueven H, Gold R, Metz I, Lühder F, Chan A.

Acta Neuropathol. 2019 Sep;138(3):443-456. doi: 10.1007/s00401-019-02018-8. Epub 2019 Apr 27.

21.

Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R.

Mult Scler Relat Disord. 2019 Jun;31:157-164. doi: 10.1016/j.msard.2019.03.022. Epub 2019 Mar 30.

22.

Functional Neurosonology Reveals Impaired Cerebrovascular Reactivity in Multiple Sclerosis.

Krogias C, Christou I, Tsivgoulis G, Koutroulou I, Schroeder C, Lantinioti C, Richter D, Karapanayiotides T, Haghikia A, Gold R, Voumvourakis K.

J Neuroimaging. 2019 Sep;29(5):589-591. doi: 10.1111/jon.12617. Epub 2019 Apr 16.

PMID:
30990241
23.

Priorities Wizard: Multisite Web-Based Primary Care Clinical Decision Support Improved Chronic Care Outcomes with High Use Rates and High Clinician Satisfaction Rates.

Sperl-Hillen JM, Rossom RC, Kharbanda EO, Gold R, Geissal ED, Elliott TE, Desai JR, Rindal DB, Saman DM, Waring SC, Margolis KL, O'Connor PJ.

EGEMS (Wash DC). 2019 Apr 3;7(1):9. doi: 10.5334/egems.284. Review.

24.

Author Correction: Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.

Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grün D, Priller J, Stadelmann C, Prinz M.

Nature. 2019 Apr;568(7751):E4. doi: 10.1038/s41586-019-1045-2.

PMID:
30918409
25.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ.

Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.

26.

A protein quality control pathway regulated by linear ubiquitination.

van Well EM, Bader V, Patra M, Sánchez-Vicente A, Meschede J, Furthmann N, Schnack C, Blusch A, Longworth J, Petrasch-Parwez E, Mori K, Arzberger T, Trümbach D, Angersbach L, Showkat C, Sehr DA, Berlemann LA, Goldmann P, Clement AM, Behl C, Woerner AC, Saft C, Wurst W, Haass C, Ellrichmann G, Gold R, Dittmar G, Hipp MS, Hartl FU, Tatzelt J, Winklhofer KF.

EMBO J. 2019 May 2;38(9). pii: e100730. doi: 10.15252/embj.2018100730. Epub 2019 Mar 18.

PMID:
30886048
27.

Observational study protocol for evaluating control of hypertension and the effects of social determinants.

Angier H, Huguet N, Marino M, Green B, Holderness H, Gold R, Hoopes M, DeVoe J.

BMJ Open. 2019 Mar 15;9(3):e025975. doi: 10.1136/bmjopen-2018-025975.

28.

Author Correction: Laquinimod treatment in the R6/2 mouse model.

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R.

Sci Rep. 2019 Mar 15;9(1):4960. doi: 10.1038/s41598-018-37926-4.

29.

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.

Vohl K, Duscha A, Gisevius B, Kaisler J, Gold R, Haghikia A.

Front Neurol. 2019 Feb 22;10:132. doi: 10.3389/fneur.2019.00132. eCollection 2019.

30.

Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct anti-oxidative effects on Schwann cells.

Pitarokoili K, Sgodzai M, Grüter T, Bachir H, Motte J, Ambrosius B, Pedreiturria X, Yoon MS, Gold R.

J Neuroinflammation. 2019 Mar 9;16(1):58. doi: 10.1186/s12974-019-1445-0.

31.

Low-radiation of technetium-99m-sestamibi and single-photon emission computed tomography/computed tomography to diagnose parathyroid lesions.

Vaiman M, Cohenpur M, Halevy A, Volkov O, Gold R, Peer M, Golan H, Gavriel H.

World J Nucl Med. 2019 Jan-Mar;18(1):52-57. doi: 10.4103/wjnm.WJNM_29_18.

32.

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G.

Ann Neurol. 2019 Apr;85(4):606-610. doi: 10.1002/ana.25437. Epub 2019 Mar 5.

PMID:
30761586
33.

Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.

Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grün D, Priller J, Stadelmann C, Prinz M.

Nature. 2019 Feb;566(7744):388-392. doi: 10.1038/s41586-019-0924-x. Epub 2019 Feb 13. Erratum in: Nature. 2019 Apr;568(7751):E4.

PMID:
30760929
34.

Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010⁻2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers.

Richter D, Bartig D, Muhlack S, Hartelt E, Scherbaum R, Katsanos AH, Müller T, Jost W, Ebersbach G, Gold R, Krogias C, Tönges L.

Cells. 2019 Feb 11;8(2). pii: E151. doi: 10.3390/cells8020151.

35.

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.

Zella MAS, Metzdorf J, Ostendorf F, Maass F, Muhlack S, Gold R, Haghikia A, Tönges L.

Cells. 2019 Jan 31;8(2). pii: E105. doi: 10.3390/cells8020105. Review.

36.

Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease.

Pesch B, Casjens S, Woitalla D, Dharmadhikari S, Edmondson DA, Zella MAS, Lehnert M, Lotz A, Herrmann L, Muhlack S, Kraus P, Yeh CL, Glaubitz B, Schmidt-Wilcke T, Gold R, van Thriel C, Brüning T, Tönges L, Dydak U.

Cells. 2019 Jan 29;8(2). pii: E96. doi: 10.3390/cells8020096.

37.

Study protocol: a pragmatic, stepped-wedge trial of tailored support for implementing social determinants of health documentation/action in community health centers, with realist evaluation.

Gold R, Bunce A, Cottrell E, Marino M, Middendorf M, Cowburn S, Wright D, Mossman N, Dambrun K, Powell BJ, Gruß I, Gottlieb L, Dearing M, Scott J, Yosuf N, Krancari M.

Implement Sci. 2019 Jan 28;14(1):9. doi: 10.1186/s13012-019-0855-9.

38.

Neutropenia at the time of subcutaneous port insertion may not be a risk factor for early infectious complications in pediatric oncology patients.

VanHouwelingen LT, Veras LV, Lu M, Wynn L, Wu J, Prajapati HJ, Gold RE, Murphy AJ, Fernandez-Pineda I, Gosain A, Pui CH, Davidoff AM.

J Pediatr Surg. 2019 Jan;54(1):145-149. doi: 10.1016/j.jpedsurg.2018.10.024. Epub 2018 Oct 5.

PMID:
30661598
39.

Toward a Common Agenda for the Public and Private Sectors to Advance Digital Health Communication.

Abroms LC, Allegrante JP, Auld ME, Gold RS, Riley WT, Smyser J.

Am J Public Health. 2019 Feb;109(2):221-223. doi: 10.2105/AJPH.2018.304806. No abstract available.

PMID:
30649936
40.

Learner Reactions to Activities Exploring Racism as a Social Determinant of Health.

Dennis SN, Gold RS, Wen FK.

Fam Med. 2019 Jan;51(1):41-47. doi: 10.22454/FamMed.2019.704337.

41.

Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.

Demir S, Pitarokoili K, Linker R, Gold R.

J Neuroimmunol. 2019 Mar 15;328:78-85. doi: 10.1016/j.jneuroim.2018.12.010. Epub 2018 Dec 27.

PMID:
30623801
42.

Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Fisse AL, Pitarokoili K, Motte J, Gamber D, Kerasnoudis A, Gold R, Yoon MS.

J Neurol. 2019 Feb;266(2):468-475. doi: 10.1007/s00415-018-9158-3. Epub 2018 Dec 15.

PMID:
30554264
43.

Treatment of an acute motor and sensory axonal neuropathy with propionate in a 33-year-old male.

Yoon MS, Pitarokoili K, Sturm D, Haghikia A, Gold R, Fisse AL.

Ther Adv Neurol Disord. 2018 Nov 3;11:1756286418809580. doi: 10.1177/1756286418809580. eCollection 2018.

44.

Emerging Immunotherapies for Parkinson Disease.

Zella SMA, Metzdorf J, Ciftci E, Ostendorf F, Muhlack S, Gold R, Tönges L.

Neurol Ther. 2019 Jun;8(1):29-44. doi: 10.1007/s40120-018-0122-z. Epub 2018 Dec 11. Review.

45.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

46.

Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Classen G, Classen C, Bernasconi C, Brandt C, Gold R, Chan A, Hoepner R.

J Neurovirol. 2019 Feb;25(1):133-136. doi: 10.1007/s13365-018-0689-2. Epub 2018 Nov 9.

PMID:
30414049
47.

Clinical, Sonographic, and Electrophysiologic Longitudinal Features of Chronic Inflammatory Demyelinating Polyneuropathy.

Fisse AL, Pitarokoili K, Trampe N, Motte J, Kerasnoudis A, Gold R, Yoon MS.

J Neuroimaging. 2019 Mar;29(2):223-232. doi: 10.1111/jon.12579. Epub 2018 Nov 8.

PMID:
30407676
48.

Successful therapy with rituximab in three patients with probable neurosarcoidosis.

Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J.

Ther Adv Neurol Disord. 2018 Oct 26;11:1756286418805732. doi: 10.1177/1756286418805732. eCollection 2018.

49.

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A.

J Neurol. 2019 Jan;266(1):57-67. doi: 10.1007/s00415-018-9092-4. Epub 2018 Oct 30.

50.

Landscape of pain in Parkinson's disease: impact of gender differences.

Zella MAS, May C, Müller T, Ahrens M, Tönges L, Gold R, Marcus K, Woitalla D.

Neurol Res. 2019 Jan;41(1):87-97. doi: 10.1080/01616412.2018.1531208. Epub 2018 Oct 12.

PMID:
30311863

Supplemental Content

Support Center